首页> 外文会议>Conference on biochemical and molecular engineering >IMPROVING THE EFFICIENCY OF HUMAN NEURAL STEM CELL DIFFERENTIATION BY TARGETING TRANSCRIPTION FACTORS TBR1 AND TBR2 WITH CRISPR-CAS9 GENOME EDITING
【24h】

IMPROVING THE EFFICIENCY OF HUMAN NEURAL STEM CELL DIFFERENTIATION BY TARGETING TRANSCRIPTION FACTORS TBR1 AND TBR2 WITH CRISPR-CAS9 GENOME EDITING

机译:通过使用CRISPR-CAS9基因组编辑靶向转录因子TBR1和TBR2来提高人类神经干细胞分化的效率

获取原文

摘要

Cell-based therapies are attractive for treating neurodegenerative diseases. Various neuronal cell lineages can be generated through stem cell differentiation to restore impaired functions. The process of differentiation depends on the presence or absence of specific transcription factors, which are cell lineage- dependent. For example, the transition between an intermediate progenitor to a postmitotic glutamatergic neuron has been correlated to the downregulation and subsequent upregulation of (T-Box, Brain) TBR2 and TBR1, respectively. This suggests that both TBR1 and TBR2 are important for the development of the glutamatergic neurons. Although different types of neuronal cells have been generated in vitro, these methods often lead to heterogeneous cell populations due to the generation of unintended/off-target cell types. Potential health risks have been associated with these off-target effects in human studies which impede the advancement of cell-based therapies. Thus, there is a need to more precisely control the lineage commitment of stem cells. To address this challenge, we created knockout of specific transcription factors in a human embryonic H9-derived neural stem cell (hNSCs) line, to restrict their lineages and reduce the heterogeneity of the cell population. We used CRISPR-Cas9 to restrict the differentiation of NSC lineages by targeting TBR1 and TBR2. Fluorescence-activated cell sorting, used to quantify the neuronal population after differentiation, showed that NSCs lacking TBR1 or TBR2 reduced the percentage of glutamatergic neurons as compared to wild-type control under the same differentiation condition. Thus, this study indicate thatthe absence of specific transcription factors can restrict lineage commitment and thereby improvethe efficacy of cell-based therapy.
机译:基于细胞的疗法对于治疗神经退行性疾病很有吸引力。可以通过干细胞分化产生各种神经元细胞谱系,以恢复受损的功能。分化过程取决于是否存在特定的转录因子,这些转录因子是细胞谱系依赖性的。例如,中间祖细胞到有丝分裂后谷氨酸能神经元之间的过渡已分别与(T-Box,Brain)TBR2和TBR1的下调和随后的上调相关。这表明TBR1和TBR2对谷氨酸能神经元的发育都很重要。尽管已经在体外产生了不同类型的神经元细胞,但是由于产生了非预期/脱靶细胞类型,这些方法经常导致异种细胞群。在人体研究中,潜在的健康风险与这些脱靶效应相关联,从而阻碍了基于细胞的疗法的发展。因此,需要更精确地控制干细胞的谱系承诺。为了解决这一挑战,我们在人类胚胎H9衍生的神经干细胞(hNSCs)系中创建了特定转录因子的基因敲除,以限制它们的谱系并减少细胞群体的异质性。我们使用CRISPR-Cas9通过靶向TBR1和TBR2来限制NSC谱系的分化。荧光激活的细胞分选用于量化分化后的神经元数量,结果表明,与相同分化条件下的野生型对照相比,缺少TBR1或TBR2的NSC减少了谷氨酸能神经元的百分比。因此,这项研究表明,缺乏特异性转录因子可以限制谱系承诺,从而提高基于细胞的疗法的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号